In this molecular subtype of breast cancers, PI3K/Akt pathway seems to have the highest impact on oncogenic potential of HER2 and the development of resistance to anti-HER2 targeted therapy (8–10). This evidence concerns the gene ERBB2 and breast carcinoma.